Scarica l'app Stockscreener
136.95
0.77%
1.04
Dopo l'orario di chiusura:
136.95
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Non-operating income (total) of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com - Investing.com India
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term - Zacks Investment Research
This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued - GuruFocus
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says - Yahoo Finance
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – FWB:NB3 - TradingView
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term - Zacks Investment Research
BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $150 - Moomoo
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Porterville Recorder
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. - Stock Titan
Neurocrine Biosciences (NBIX) After New VYKAT XR Data Why The Undervalued Narrative Persists - Simply Wall Street
Neurocrine Biosciences stock fell 1.4 percent before research event - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock - ChartMill
Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high - AD HOC NEWS
Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst - Moomoo
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board - Endpoints News
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Australia
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference - PR Newswire
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
Neurocrine Biosciences selects Ruder Finn as communications AOR - Medical Marketing and Media
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance UK
UBS cuts Neurocrine Biosciences stock price target to $214 on competition - Investing.com
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
EBITDA margin % of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return - Simply Wall Street
Neurocrine Biosciences names Eiry Roberts as chief medical officer - Investing.com
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - marketscreener.com
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - Yahoo Finance
Neurocrine names Eiry Roberts chief medical officer - Stock Titan
Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes - marketscreener.com
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - PR Newswire
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - Nasdaq
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - easternprogress.com
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - simplywall.st
4.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):